Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial

RCT (n=170) found dasiglucagon, a ready-to-use, next-generation glucagon analogue in aqueous formulation for subcut use provided rapid and effective reversal of hypoglycaemia in adults with type 1 diabetes, with similar safety and tolerability to reconstituted glucagon injection.

SPS commentary:

In the study, the median time to recovery was 10 minutes for dasiglucagon compared with 40 minutes for placebo (p<0.001); the corresponding result for reconstituted lyophilised glucagon, included as reference, was 12 minutes.

Diabetes Care